Sentinel Lymph Node Biopsy is Feasible for Breast Cancer Patients after Neoadjuvant Chemotherapy

この論文にアクセスする

この論文をさがす

著者

抄録

Background: Despite the increasing use of both sentinel lymph node (SLN) biopsy and neoadjuvant chemotherapy (NAC) in patients with operable breast cancer, information on the feasibility and accuracy of sentinel node biopsy following neoadjuvant chemotherapy is still quite limited. Therefore, we investigated the feasibility and accuracy of sentinel lymph node biopsy for breast cancer patients after NAC.<br>Methods: A total of 104 patients with Stage II and III breast cancers, previously treated by NAC, were enrolled in the study. All patients were clinically node-negative after NAC. The patients underwent SLN biopsy, which involved a combination of an intradermal injection of radiocolloid and a subareolar injection of blue dye over the tumor. This was followed by completion axillary lymph node dissection (ALND).<BR>Results: SLN could be identified in 97 of 104 patients (identification rate, 93.3%). In 93 of the 97 patients (95.9%), the SLN accurately predicted the axillary status. Four patients' SLN biopsies were false negative, resulting in a false-negative rate of 10.0%. The SLN identification rate tended to be lower among patients with T4 primary tumors prior to NAC (62.5%).<BR>Conclusion: The SLN identification and false-negative rates were similar to rates in non-neoadjuvant studies. The SLN accurately predicted metastatic disease in the axilla of patients with tumor response following NAC.

収録刊行物

  • Breast cancer : the journal of the Japanese Breast Cancer Society  

    Breast cancer : the journal of the Japanese Breast Cancer Society 14(1), 10-15, 2007-01-01 

    The Japanese Breast Cancer Society

参考文献:  20件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

被引用文献:  3件

被引用文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10018815176
  • NII書誌ID(NCID)
    AA1103354X
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    13406868
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ